Logo image of KAPA

KAIROS PHARMA LTD (KAPA) Stock Fundamental Analysis

NYSEARCA:KAPA - NYSE Arca - US48301N1046 - Common Stock - Currency: USD

0.71  0 (-0.14%)

After market: 0.6997 -0.01 (-1.45%)

Fundamental Rating

3

KAPA gets a fundamental rating of 3 out of 10. The analysis compared the fundamentals against 560 industry peers in the Biotechnology industry. No worries on liquidiy or solvency for KAPA as it has an excellent financial health rating, but there are worries on the profitability. KAPA is valued expensive and it does not seem to be growing.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

KAPA had negative earnings in the past year.
KAPA had a negative operating cash flow in the past year.
KAPA Yearly Net Income VS EBIT VS OCF VS FCFKAPA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2021 2022 2023 2024 0 -1M -2M -3M

1.2 Ratios

KAPA has a Return On Assets of -44.63%. This is comparable to the rest of the industry: KAPA outperforms 52.85% of its industry peers.
With a decent Return On Equity value of -49.66%, KAPA is doing good in the industry, outperforming 65.84% of the companies in the same industry.
Industry RankSector Rank
ROA -44.63%
ROE -49.66%
ROIC N/A
ROA(3y)-111.42%
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
KAPA Yearly ROA, ROE, ROICKAPA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2021 2022 2023 2024 0 100 -100 -200

1.3 Margins

KAPA does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
KAPA Yearly Profit, Operating, Gross MarginsKAPA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2021 2022 2023 2024

More info and screens

8

2. Health

2.1 Basic Checks

Compared to 1 year ago, KAPA has more shares outstanding
KAPA has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
KAPA Yearly Shares OutstandingKAPA Yearly Shares OutstandingYearly Shares Outstanding 2021 2022 2023 2024 2M 4M 6M 8M 10M
KAPA Yearly Total Debt VS Total AssetsKAPA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2021 2022 2023 2024 1M 2M 3M 4M 5M

2.2 Solvency

An Altman-Z score of 6.55 indicates that KAPA is not in any danger for bankruptcy at the moment.
KAPA's Altman-Z score of 6.55 is amongst the best of the industry. KAPA outperforms 81.14% of its industry peers.
KAPA has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 6.55
ROIC/WACCN/A
WACCN/A
KAPA Yearly LT Debt VS Equity VS FCFKAPA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2021 2022 2023 2024 0 2M -2M 4M

2.3 Liquidity

KAPA has a Current Ratio of 7.52. This indicates that KAPA is financially healthy and has no problem in meeting its short term obligations.
KAPA has a better Current ratio (7.52) than 68.86% of its industry peers.
KAPA has a Quick Ratio of 7.52. This indicates that KAPA is financially healthy and has no problem in meeting its short term obligations.
KAPA has a better Quick ratio (7.52) than 69.22% of its industry peers.
Industry RankSector Rank
Current Ratio 7.52
Quick Ratio 7.52
KAPA Yearly Current Assets VS Current LiabilitesKAPA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2021 2022 2023 2024 1M 2M 3M 4M

More info and screens

0

3. Growth

3.1 Past

KAPA shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -62.44%.
EPS 1Y (TTM)-62.44%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-215.48%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

KAPA is expected to show a very negative growth in Earnings Per Share. In the coming years, the EPS will decrease by -42.33% yearly.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y-41.67%
EPS Next 2Y-46.06%
EPS Next 3Y-42.33%
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
KAPA Yearly EPS VS EstimatesKAPA Yearly EPS VS EstimatesYearly EPS VS Estimates 2024 2025 2026 2027 -0.1 -0.2 -0.3 -0.4 -0.5

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

KAPA reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year KAPA is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
KAPA Price Earnings VS Forward Price EarningsKAPA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80 100

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
KAPA Per share dataKAPA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.2 -0.2 0.4 -0.4

4.3 Compensation for Growth

KAPA's earnings are expected to decrease with -42.33% in the coming years. This may justify a cheaper valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-46.06%
EPS Next 3Y-42.33%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for KAPA!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

KAIROS PHARMA LTD

NYSEARCA:KAPA (7/11/2025, 8:04:00 PM)

After market: 0.6997 -0.01 (-1.45%)

0.71

0 (-0.14%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)05-14 2025-05-14/bmo
Earnings (Next)N/A N/A
Inst Owners9.36%
Inst Owner Change0%
Ins Owners40.29%
Ins Owner Change0%
Market Cap11.96M
Analysts82.22
Price Target8.5 (1097.18%)
Short Float %2.17%
Short Ratio0.19
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-90.48%
Min EPS beat(2)-124.09%
Max EPS beat(2)-56.86%
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)28.2%
EPS NQ rev (1m)0%
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)-23.19%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 1.68
P/tB 1.72
EV/EBITDA N/A
EPS(TTM)-0.27
EYN/A
EPS(NY)-0.44
Fwd EYN/A
FCF(TTM)-0.28
FCFYN/A
OCF(TTM)-0.28
OCFYN/A
SpS0
BVpS0.42
TBVpS0.41
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -44.63%
ROE -49.66%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-111.42%
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score5
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 7.52
Quick Ratio 7.52
Altman-Z 6.55
F-Score5
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-62.44%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-215.48%
EPS Next Y-41.67%
EPS Next 2Y-46.06%
EPS Next 3Y-42.33%
EPS Next 5YN/A
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-36.7%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-397.41%
EBIT Next 3Y-147.89%
EBIT Next 5YN/A
FCF growth 1Y-4982.72%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-4982.72%
OCF growth 3YN/A
OCF growth 5YN/A